AZNAstraZenecaRunning, no new patients
Study of AZD2811 + Durvalumab in ES-SCLC
Small-Cell Lung Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 31 (final count)
- Started
- Feb 23, 2021
- Main results expected
- Jun 18, 2022
- Fully finished
- Dec 1, 2026
- Results posted
- Mar 27, 2025
What counts as success
The trial's main goal(s), called the “primary outcome.”
Maintenance Participants Alive and Progression Free (APF12) Per RECIST 1.1 [Efficacy]
Measured over: Up to 12 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT04745689 · record last updated 2026-07-06 · checked 2026-11-09 15:47 UTC